17025209

Source:http://linkedlifedata.com/resource/pubmed/id/17025209

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006826, umls-concept:C0008838, umls-concept:C0013089, umls-concept:C0025677, umls-concept:C0036525, umls-concept:C0042670, umls-concept:C0045093, umls-concept:C0065452, umls-concept:C0087111, umls-concept:C0205179, umls-concept:C0879626, umls-concept:C1522484, umls-concept:C1707455
pubmed:issue	6
pubmed:dateCreated	2006-10-9
pubmed:abstractText	Cisplatin-based combination chemotherapy has been considered as standard therapy for advanced or metastatic urothelial carcinoma. A recent study has, however, revealed that gemcitabine may have the potential to act synergistically with cisplatin. Therefore, the side effects of gemcitabine plus cisplatin (GC) therapy were compared with those of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) therapy in patients with advanced or metastatic urothelial carcinoma.
pubmed:language	jpn
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/2984841R
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate, http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine, http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	0021-5287
pubmed:author	pubmed-author:HamadaHitoshiH, pubmed-author:IkedaTetsuhiroT, pubmed-author:MiyauchiYuukiY, pubmed-author:OchiTatsumasaT, pubmed-author:OzawaAkiraA, pubmed-author:ShimamotoKenjiK, pubmed-author:SugawaraTsuyoshiT, pubmed-author:TanjiNozomuN, pubmed-author:ToshinoAkihikoA, pubmed-author:YanagakiTakahiroT, pubmed-author:YanagiharaYutakaY, pubmed-author:YokoyamaMasayoshiM
pubmed:issnType	Print
pubmed:volume	97
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	777-81
pubmed:dateRevised	2011-7-28
pubmed:meshHeading	pubmed-meshheading:17025209-Adult, pubmed-meshheading:17025209-Aged, pubmed-meshheading:17025209-Aged, 80 and over, pubmed-meshheading:17025209-Alopecia, pubmed-meshheading:17025209-Anorexia, pubmed-meshheading:17025209-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17025209-Cisplatin, pubmed-meshheading:17025209-Deoxycytidine, pubmed-meshheading:17025209-Doxorubicin, pubmed-meshheading:17025209-Drug Administration Schedule, pubmed-meshheading:17025209-Female, pubmed-meshheading:17025209-Humans, pubmed-meshheading:17025209-Male, pubmed-meshheading:17025209-Methotrexate, pubmed-meshheading:17025209-Middle Aged, pubmed-meshheading:17025209-Neoplasm Staging, pubmed-meshheading:17025209-Quality of Life, pubmed-meshheading:17025209-Urologic Neoplasms, pubmed-meshheading:17025209-Vinblastine
pubmed:year	2006
pubmed:articleTitle	[Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].
pubmed:affiliation	Department of Urology, Saiseikai Saijo Hospital.
pubmed:publicationType	Journal Article, Comparative Study, English Abstract